Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 1
Submit an article Journal homepage
174
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review

Sarah Marshall Institute of Cardiovascular & Medical Sciences, University of Glasgow, Walton Building, Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK
,
Patricia Fearon Institute of Cardiovascular & Medical Sciences, University of Glasgow, Walton Building, Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK
,
Jesse Dawson Institute of Cardiovascular & Medical Sciences, University of Glasgow, Walton Building, Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK
&
Terence J Quinn Institute of Cardiovascular & Medical Sciences, University of Glasgow, Walton Building, Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK. [email protected]
Pages 29-42 | Published online: 09 Jan 2014

References

  • Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 104(11), 1534–1539 (2009).
  • Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2), 119–125 (2006).
  • Gage BF, van Walraven C, Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110(16), 2287–2292 (2004).
  • Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol. 57(2), 173–180 (2011).
  • Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137(2), 263–272 (2010).
  • Rosamond W, Flegal K, Furie K et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25–e146 (2008).
  • Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 37(10), 2579–2587 (2006).
  • Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin. Neurol. 30(5), 565–572 (2010).
  • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857–867 (2007).
  • Connolly S, Pogue J, Hart R; on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 367, 1903–1912 (2006).
  • Mant J, Hobbs FD, Fletcher K et al.; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370(9586), 493–503 (2007).
  • Sato H, Ishikawa K, Kitabatake A et al.; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 37(2), 447–451 (2006).
  • Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analyses of pooled data from five randomized controlled trials. Arch. Int. Med. 154, 1449–1457 (1994).
  • McArthur KS, Quinn TJ, Higgins P, Langhorne P. Post-acute care and secondary prevention after ischaemic stroke. BMJ 342, d2083 (2011).
  • Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation: implications for thromboprophylaxis. J. Am. Coll. Cardiol. 56, 827–837 (2010).
  • Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb. Res. 124(1), 37–41 (2009).
  • Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15(3), 244–252 (2009).
  • Avery T, Barber N, Ghaleb M et al. Investigating the prevalence and causes of prescribing errors in general practice: the PRACtICe Study. General Medical Council (UK) Report (2012).
  • Kent AJ, O’Beirne J, Negus R. The patient with haematemesis and melaena. Acute Med. 10(1), 45–49 (2011).
  • Olsen SB; on behalf of the Executive Steering Committee of the SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximalegatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III) randomized controlled trial. Lancet 362, 1691–1698 (2003).
  • Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N. Engl. J. Med. 353(10), 1028–1040 (2005).
  • Eriksson BI, Dahl OE, Rosencher N et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 5(11), 2178–2185 (2007).
  • Ginsberg JS, Davidson BL Comp PC; on behalf of the RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J. Arhroplasty. 24, 1–9 (2008).
  • Eriksson BI, Dahl OE, Rosencher N et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591), 949–956 (2007).
  • Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100(9), 1419–1426 (2007).
  • Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
  • Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med. 363(19), 1875–1876 (2010).
  • Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293, 690–698 (2005).
  • Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883–891 (2011).
  • Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981–992 (2011).
  • Wallentin L, Yusuf S, Ezekowitz MD et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745), 975–983 (2010).
  • Diener HC, Connolly SJ, Ezekowitz MD et al.; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 9(12), 1157–1163 (2010).
  • Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123(21), 2363–2372 (2011).
  • Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors – catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J. Neurosurg. 116(5), 1093–1096 (2012).
  • Boehringer Ingelheim Drug Safety Database. Suspected cases reported from March 2008–October 2011 (2012).
  • Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296–1310 (2001).
  • Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125(5), 669–676 (2012).
  • Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. 172(5), 397–402 (2012).
  • Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107(3), 584–589 (2012).
  • Fuster V, Ryden LE, Cannom DS et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123, e269–e367 (2011).
  • Skanes AC, Healey JS, Cairns JA et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28(2), 125–136 (2012).
  • Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev. Pharmacoecon. Outcomes Res. 11(1), 9–25 (2011).
  • Freeman JV, Zhu RP, Owens DK et al. Cost–effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann. Intern. Med. 154, 1–11 (2011).
  • Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch. Intern. Med. 156(16), 1829–1836 (1996).
  • O’Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293(6), 699–706 (2005).
  • Freeman JV, Turakhia MP. Letter. Ann. Int. Med. 154(8), 570–571 (2011).
  • Sorensen SV, Kansal AR, Connolly S et al. Cost–effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb. Haemost. 105(5), 908–919 (2011).
  • van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 131(5), 1508–1515 (2007).
  • Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb. Haemost. 104(6), 1106–1115 (2010).
  • Mittman N, Saing SI, Sharma M et al. Impact of disability status on ischaemic stroke costs. Stroke 41, e390 (2010).
  • Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost–effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 24(10), 1021–1033 (2006).
  • Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 21(3), 191–200 (2003).
  • Shah SV, Gage BF. Cost–effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123(22), 2562–2570 (2011).
  • Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 343, d6333 (2011).
  • Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making 26(4), 410–420 (2006).
  • Kamel H, Johnston SC, Easton JD, Kim AS. Cost–effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 43(3), 881–883 (2012).
  • Quinn TJ, Dawson J. Acute ‘strokenomics’: efficacy and economic analyses of alteplase for acute ischemic stroke. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 513–522 (2009).
  • Contractor T, Khasnis A. Left atrial appendage closure in atrial fibrillation: a world without anticoagulation? Cardiol. Res. Pract. 30, 752–808 (2011).
  • Healey JS, Connolly SJ, Gold MR et al.; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N. Engl. J. Med. 366(2), 120–129 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.